Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albendazole + ivermectin (Azista Bhutan Healthcare)
- Development stage
- Unknown
- Lead developer
- Azista Bhutan Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aziworm is a branded generic combination medication consisting of albendazole and ivermectin, produced by Azista Bhutan Healthcare. This combination is utilized for its synergistic broad-spectrum anthelmintic activity against a variety of intestinal and systemic parasites. Albendazole, a benzimidazole derivative, interferes with the polymerization of tubulin, disrupting the microtubule-mediated uptake of glucose and leading to the parasite's energy depletion. Ivermectin, a macrocyclic lactone, binds selectively to glutamate-gated chloride channels in invertebrate nerve and muscle cells, increasing permeability to chloride ions and resulting in hyperpolarization, paralysis, and death of the parasite. Aziworm is primarily indicated for the treatment of mixed helminthic infestations, including lymphatic filariasis, strongyloidiasis, and soil-transmitted helminthiases.
- Brand names
- Aziworm
- Other names
- albendazole + ivermectin
02
Targets
GluCl (Glutamate-gated chloride channel)Glycine receptorNicotinic Acetylcholine ReceptorP2X4 (P2X purinoceptor 4)TUBB (Tubulin (alpha and beta subunits))GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on albendazole + ivermectin (Azista Bhutan Healthcare).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albendazole + ivermectin (Azista Bhutan Healthcare).